HK Stock Market Move | CHINA BLUECHEM(03983) falls by more than 5% again, with annual net profit decreasing by over 9% year-on-year. Institutions believe that a high dividend payout is expected to be maintained.
CNOOC Chemicals (03983) fell more than 5% again, as of the time of publication, it fell 4.73% to HKD 2.82, with a turnover of HKD 53.2381 million.
CHINA BLUECHEM (03983) fell by over 5% again, dropping by 4.73% to HK$2.82 as of the time of writing, with a trading volume of HK$53.2381 million.
In terms of news, CHINA BLUECHEM released its annual performance, with sales revenue of approximately 12.034 billion yuan, a year-on-year increase of 0.7%. The company's attributable net profit was around 974 million yuan, a year-on-year decrease of 9.04%. The announcement stated that the growth in revenue was mainly due to fluctuations in the fertilizer and chemical product markets, as well as the impact of increased production efficiency by production units. Gross profit was 1.571 billion yuan, a year-on-year decrease of 7.9%, mainly affected by factors such as the decline in urea prices and the rise in costs of phosphate compound fertilizers.
Globe Prosperity released a research report stating that the company's 25-year performance is slightly under pressure. The company has maintained a dividend payout ratio of over 50% in the past two years, and due to the company's ample funds and consideration for the requirements of state-owned enterprise market value management, they are confident in maintaining a dividend payout ratio of over 50% in the next two years.
Related Articles

HENLIUS (02696)Naluriyou monoclonal anti-drug similar to drug HLX18 (recombinant humanized monoclonal antibody injection) for the treatment of various solid tumors has received approval from the National Medical Products Administration for phase 1 clinical trial application.

Chengdu Wintrue Holding (002539.SZ): 700,000 tons of synthetic ammonia project completed trial production.

ONEWO (02602) spent approximately HKD 4.7346 million on March 20 to repurchase 270,000 shares.
HENLIUS (02696)Naluriyou monoclonal anti-drug similar to drug HLX18 (recombinant humanized monoclonal antibody injection) for the treatment of various solid tumors has received approval from the National Medical Products Administration for phase 1 clinical trial application.

Chengdu Wintrue Holding (002539.SZ): 700,000 tons of synthetic ammonia project completed trial production.

ONEWO (02602) spent approximately HKD 4.7346 million on March 20 to repurchase 270,000 shares.

RECOMMEND

State Reform Fund And Three Major Banks Backstop Voyah As It Secures Hong Kong’s First Auto IPO This Year
20/03/2026

Hong Kong IPO Irregularities Surface As Corner Placements And Retail Losses Emerge, Haizhi Technology Implicated
20/03/2026

Gold And Silver Experience Sharp Sell‑Off As Global Rate‑Hike Expectations Intensify
20/03/2026


